a1 The Center for Botanical Lipids and Inflammatory Disease Prevention, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
a2 Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
a3 Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
a4 Center for Human Genomics, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
a5 Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
a6 Department of Physiology/Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
a7 Division of General Internal Medicine, Department of Medicine, The Johns Hopkins University, Baltimore, MD 21224, USA
a8 Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
a9 Division of Allergy and Clinical Immunology, Department of Medicine, The Johns Hopkins University, Baltimore, MD 21224, USA
Abstract
Over the past 50 years, increases in dietary n-6 PUFA, such as linoleic acid, have been hypothesised to cause or exacerbate chronic inflammatory diseases. The present study examines an individual's innate capacity to synthesise n-6 long-chain PUFA (LC-PUFA) with respect to the fatty acid desaturase (FADS) locus in Americans of African and European descent with diabetes or the metabolic syndrome. Compared with European Americans (EAm), African Americans (AfAm) exhibited markedly higher serum levels of arachidonic acid (AA) (EAm 7·9 (sd 2·1), AfAm 9·8 (sd 1·9) % of total fatty acids; P < 2·29 × 10− 9) and the AA:n-6-precursor fatty acid ratio, which estimates FADS1 activity (EAm 5·4 (sd 2·2), AfAm 6·9 (sd 2·2); P = 1·44 × 10− 5). In all, seven SNP mapping to the FADS locus revealed strong association with AA, EPA and dihomo-γ-linolenic acid (DGLA) in the EAm. Importantly, EAm homozygous for the minor allele (T) had significantly lower AA levels (TT 6·3 (sd 1·0); GG 8·5 (sd 2·1); P = 3·0 × 10− 5) and AA:DGLA ratios (TT 3·4 (sd 0·8), GG 6·5 (sd 2·3); P = 2·2 × 10− 7) but higher DGLA levels (TT 1·9 (sd 0·4), GG 1·4 (sd 0·4); P = 3·3 × 10− 7) compared with those homozygous for the major allele (GG). Allele frequency patterns suggest that the GG genotype at rs174537 (associated with higher circulating levels of AA) is much higher in AfAm (0·81) compared with EAm (0·46). Similarly, marked differences in rs174537 genotypic frequencies were observed in HapMap populations. These data suggest that there are probably important differences in the capacity of different populations to synthesise LC-PUFA. These differences may provide a genetic mechanism contributing to health disparities between populations of African and European descent.
(Received December 10 2010)
(Revised April 11 2011)
(Accepted May 05 2011)
(Online publication July 04 2011)
Key Words:
Correspondence:
c1 Corresponding author: Dr Floyd H. Chilton, fax +1 336 716 8501, email schilton@wakehealth.edu
Footnotes
Abbreviations: AA, arachidonic acid; DGLA, dihomo-γ-linolenic acid; DHS, Diabetes Heart Study; FADS, fatty acid desaturase; GLA, γ-linolenic acid; LA, linoleic acid; LC-PUFA, long-chain PUFA; LD, linkage disequilibrium